In recently concluded clinical studies, the novel HIV drug dolutegravir has shown effectiveness in treating patients who are anti-retroviral naive and for those who are infected with a virus that is resistant to more than 2 classes of retrovirals, but who are naive to INSTIS. The studies had shown that resistance had developed slower with dolutegravir than with raltegravir, another INSTI. Dolutegravir is dosed once a day, an advantage over currently available therapy, and it was generally well tolerated with hypersensitivity occurring in less than 1% of patients. Further studies are needed in order to determine dolutegravir’s place in therapy. How do you counsel your patients to improve adherence and to prevent increasing HIV resistance?
Find out more from JAMA